CN108774237A - 新的三环化合物 - Google Patents

新的三环化合物 Download PDF

Info

Publication number
CN108774237A
CN108774237A CN201810448360.6A CN201810448360A CN108774237A CN 108774237 A CN108774237 A CN 108774237A CN 201810448360 A CN201810448360 A CN 201810448360A CN 108774237 A CN108774237 A CN 108774237A
Authority
CN
China
Prior art keywords
pyrrolo
pyrazin
ethyl
triazolo
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810448360.6A
Other languages
English (en)
Chinese (zh)
Inventor
N.维沙特
M.A.阿吉里亚迪
D.J.考德伍德
A.M.埃里克松
B.A.费亚蒙戈
K.E.弗兰克
M.弗里德曼
D.M.乔治
E.R.格德肯
N.S.约瑟夫索恩
B.C.李
M.J.莫里特科
K.D.斯图尔特
J.W.沃斯
G.A.华莱士
L.王
K.R.沃勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108774237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN108774237A publication Critical patent/CN108774237A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
CN201810448360.6A 2009-12-01 2010-12-01 新的三环化合物 Pending CN108774237A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26556309P 2009-12-01 2009-12-01
US61/265563 2009-12-01
US36411610P 2010-07-14 2010-07-14
US61/364116 2010-07-14
CN201080062920.6A CN102711476B (zh) 2009-12-01 2010-12-01 新的三环化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080062920.6A Division CN102711476B (zh) 2009-12-01 2010-12-01 新的三环化合物

Publications (1)

Publication Number Publication Date
CN108774237A true CN108774237A (zh) 2018-11-09

Family

ID=44070404

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201810902092.0A Active CN109053742B (zh) 2009-12-01 2010-12-01 新的三环化合物
CN201410571754.2A Active CN104370909B (zh) 2009-12-01 2010-12-01 三环化合物
CN201080062920.6A Active CN102711476B (zh) 2009-12-01 2010-12-01 新的三环化合物
CN201810448360.6A Pending CN108774237A (zh) 2009-12-01 2010-12-01 新的三环化合物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201810902092.0A Active CN109053742B (zh) 2009-12-01 2010-12-01 新的三环化合物
CN201410571754.2A Active CN104370909B (zh) 2009-12-01 2010-12-01 三环化合物
CN201080062920.6A Active CN102711476B (zh) 2009-12-01 2010-12-01 新的三环化合物

Country Status (41)

Country Link
US (5) US8426411B2 (fr)
EP (3) EP2506716B1 (fr)
JP (3) JP5607174B2 (fr)
KR (3) KR20180101626A (fr)
CN (4) CN109053742B (fr)
AR (1) AR079234A1 (fr)
AU (4) AU2010326108C1 (fr)
BR (1) BR112012013349B1 (fr)
CA (2) CA2781891C (fr)
CL (1) CL2012001397A1 (fr)
CO (1) CO6561771A2 (fr)
CR (2) CR20170159A (fr)
CY (2) CY1119175T1 (fr)
DK (1) DK2506716T3 (fr)
DO (2) DOP2012000151A (fr)
EC (1) ECSP12011979A (fr)
ES (1) ES2637588T3 (fr)
HK (1) HK1256947A1 (fr)
HR (1) HRP20171175T1 (fr)
HU (2) HUE033099T2 (fr)
IL (4) IL220054A (fr)
LT (2) LT2506716T (fr)
LU (1) LUC00149I2 (fr)
ME (1) ME02800B (fr)
MX (1) MX346959B (fr)
MY (1) MY167076A (fr)
NL (1) NL301035I2 (fr)
NO (1) NO2020006I1 (fr)
NZ (1) NZ600161A (fr)
PE (1) PE20121336A1 (fr)
PH (2) PH12012501076B1 (fr)
PL (1) PL2506716T3 (fr)
PT (1) PT2506716T (fr)
RS (1) RS56317B1 (fr)
RU (2) RU2711869C3 (fr)
SG (2) SG181472A1 (fr)
SI (1) SI2506716T1 (fr)
TW (3) TW201802091A (fr)
UY (1) UY33071A (fr)
WO (1) WO2011068881A1 (fr)
ZA (1) ZA201203999B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015105591A (ru) 2008-06-10 2015-08-10 Эббви Инк. Новые трициклические соединения
CA2758359A1 (fr) * 2009-04-14 2010-10-21 Astellas Pharma Inc. Derive de pyrrolopyridine condense
JP5607174B2 (ja) 2009-12-01 2014-10-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
AU2010326030A1 (en) * 2009-12-01 2012-06-07 Abbvie Inc. Novel tricyclic compounds
WO2011086053A1 (fr) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Composés hétérocycliques tricycliques, leurs compositions et procédés d'utilisation
CN103547580B (zh) * 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
BR112013026744B1 (pt) 2011-04-21 2022-05-17 Origenis Gmbh Compostos heterocíclicos, seus usos e seus intermediários, e composição farmacêutica
WO2013007765A1 (fr) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Composés tricycliques fusionnés utilisés en tant qu'inhibiteurs des janus kinases
BR112014002472A2 (pt) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
US20130072470A1 (en) * 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
CN102516146B (zh) * 2011-11-24 2013-10-02 爱斯特（成都）生物制药有限公司 5位为氮的四元氮杂螺环衍生物及其制备方法和用途
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
IN2015DN02008A (fr) * 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
WO2014060113A1 (fr) 2012-10-19 2014-04-24 Origenis Gmbh Nouveaux inhibiteurs de kinases
EP2955181B1 (fr) 2013-02-08 2019-10-30 Nissan Chemical Corporation Composé pyrrolopyridine tricyclique et inhibiteur de jak
EP3290421B1 (fr) 2013-02-22 2019-01-02 Pfizer Inc Combinaison de dérivés de pyrrolo-[2,3-d]pyrimidine et un ou plusieurs principes supplémentaires en tant qu'inhibiteurs des janus kinases (jak)
JP6581509B2 (ja) 2013-02-28 2019-09-25 ティーウィノット テクノロジーズ リミテッド 化合物を合成する化学工学プロセス及び装置
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015061665A1 (fr) 2013-10-24 2015-04-30 Abbvie Inc. Inhibiteur sélectif de jak1 et ses utilisations
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015157504A1 (fr) * 2014-04-11 2015-10-15 Taipei Medical University Inhibiteurs de l'histone désacétylase
WO2015174376A1 (fr) 2014-05-14 2015-11-19 日産化学工業株式会社 Composé tricyclique et inhibiteur de jak
EP3169315B1 (fr) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
EP3180344B1 (fr) 2014-08-12 2019-09-18 Pfizer Inc Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase
AU2015308136B2 (en) 2014-08-25 2020-07-09 Teewinot Technologies Limited Apparatus and methods for the simultaneous production of cannabinoid compounds
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US12570664B2 (en) * 2015-10-16 2026-03-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en) * 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3402798B1 (fr) 2016-01-14 2021-04-28 Handok Inc. Composés antagonistes du récepteur a3 de l'adénosine, leur procédé de préparation et leur utilisation médicale
EP3433615A1 (fr) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Procédés de diagnostic et de traitement de lentigos séniles
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
TWI851536B (zh) 2017-03-09 2024-08-11 美商艾伯維有限公司 治療克羅恩氏病和潰瘍性結腸炎之方法
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2018167283A1 (fr) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le diagnostic et le traitement d'un remodelage neuronal associé à un adénocarcinome canalaire pancréatique
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019057103A1 (fr) * 2017-09-21 2019-03-28 上海华汇拓医药科技有限公司 Inhibiteur de jak, procédé de préparation de celui-ci et application dans le domaine de la médecine
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
HUE069611T2 (hu) * 2018-08-31 2025-03-28 Suzhou Pengxu Pharmatech Co Ltd Eljárások upadacitinib és intermedierjei szintézisére
CN110872250B (zh) * 2018-08-31 2023-01-10 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成乌西替尼中的用途
EP3856742B1 (fr) 2018-11-01 2024-10-02 Lynk Pharmaceuticals Co. Ltd. Inhibiteurs de janus kinase 1 tricycliques, et compositions et procédés associés
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
CN111217819B (zh) * 2018-11-27 2021-05-14 杭州科巢生物科技有限公司 乌帕替尼的合成方法
WO2020115212A1 (fr) 2018-12-05 2020-06-11 Lek Pharmaceuticals D.D. Sel de phosphate cristallin de l'upadacitinib inhibiteur sélectif de jak1
WO2020115213A1 (fr) 2018-12-07 2020-06-11 Lek Pharmaceuticals D.D. Solvate d'un inhibiteur sélectif de jak1
CN109761885B (zh) * 2019-02-21 2020-06-26 北京悦康科创医药科技股份有限公司 一种阿加曲班异构体杂质的拆分方法
US20210380596A1 (en) * 2019-03-01 2021-12-09 Crystal Pharmaceutical (Suzhou) Co., Ltd. Upadacitinib crystal form and preparation method therefor and use thereof
PH12021552130A1 (en) 2019-03-05 2022-08-31 Incyte Corp Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
KR102737181B1 (ko) 2019-03-14 2024-12-02 상하이 시너지 파마슈티컬 사이언시스 코., 엘티디. Jak 억제제 및 그 제조방법과 의약분야에서의 응용
WO2020202183A1 (fr) 2019-03-29 2020-10-08 Mylan Laboratories Limited Procédé de préparation d'upadacitinib et de ses intermédiaires
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
EP4006028B1 (fr) * 2019-07-26 2025-07-02 Zhuhai Yufan Biotechnologies Co., Ltd Inhibiteur de la kinase irak4 et son procédé de préparation
CN110938048B (zh) * 2019-12-02 2023-03-28 四川大学 路易酸催化的插入反应高效合成二氢呋喃衍生物
WO2021113462A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Dérivés d'un inhibiteur de fgfr
JP7648027B2 (ja) * 2019-12-19 2025-03-18 クリア、スペイン、エセ、ア、ウ ウパダシチニブの調製のための方法及び中間体
CN111007184B (zh) * 2019-12-30 2023-05-16 天津天士力圣特制药有限公司 一种4-甲基哌嗪-1-甲酰氯盐酸盐含量的检测方法
WO2021176473A1 (fr) 2020-03-05 2021-09-10 Mylan Laboratories Limited Procédé de préparation d'upadacitinib et de ses intermédiaires
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
US20210371389A1 (en) * 2020-04-24 2021-12-02 Kansas Soybean Commission One-step synthesis of soybean polyols
WO2021244323A1 (fr) * 2020-06-05 2021-12-09 苏州科睿思制药有限公司 Forme cristalline d'upadacitinib, son procédé de préparation et son utilisation
KR20230038229A (ko) 2020-07-08 2023-03-17 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
WO2022044037A1 (fr) 2020-08-24 2022-03-03 Mylan Laboratories Limited Procédé amélioré pour la préparation d'intermédiaires d'upadacitinib
CA3192563A1 (fr) * 2020-09-14 2022-03-17 Gilles Ouvry Nouveaux composes inhibiteurs de jak, methode de synthese associee et utilisation associee
CA3190745A1 (fr) * 2020-10-08 2022-04-14 Dhananjay G. Sathe Composes tricycliques substitues
CN112578034B (zh) * 2020-11-04 2022-02-11 广东众生睿创生物科技有限公司 一种手性胺小分子及其盐的质量控制方法
CN114790208B (zh) * 2021-01-26 2024-06-07 珠海宇繁生物科技有限责任公司 一种irak4激酶抑制剂及其制备方法
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
MX2023011863A (es) * 2021-04-07 2023-12-15 Abbvie Inc Cocristales de upadacitinib.
CN113200967B (zh) * 2021-05-07 2022-05-24 中国人民解放军陆军军医大学 吲哚苯醌类化合物、其制备方法及其应用
US20250206717A1 (en) * 2021-05-13 2025-06-26 Innovstone Therapeutics Limited Compound having anti-tumor activity and use thereof
CN113603693B (zh) * 2021-07-13 2022-08-26 陕西丽彩药业有限公司 一种2-溴-5-对甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪的制备方法
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
EP4215196A1 (fr) 2022-01-24 2023-07-26 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un inhibiteur de jak
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
CN116836171B (zh) * 2023-06-30 2024-06-04 凌科药业(杭州)有限公司 一种磺酰胺类化合物及其应用
WO2025102268A1 (fr) * 2023-11-15 2025-05-22 Lynk Pharmaceuticals Co. Ltd. Formes à l'état solide, compositions pharmaceutiques et procédés de préparation et utilisation associés
CN117285537B (zh) * 2023-11-27 2024-02-06 中节能万润股份有限公司 一种乌帕替尼的制备方法

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053474A (en) * 1976-04-21 1977-10-11 E. R. Squibb & Sons, Inc. Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
WO1995019970A1 (fr) * 1994-01-25 1995-07-27 Warner-Lambert Company Composes tricycliques pouvant inhiber les tyrosines kinases de la famille des recepteurs du facteur de croissance epidermique
WO1999045009A1 (fr) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Inhibiteurs de la proteine tyrosine kinase, a base d'imidazopyrazine a substitution heterocyclo
JP2001233876A (ja) * 1999-12-13 2001-08-28 Eisai Co Ltd 三環式縮合異項環化合物、その製造法およびその医薬
WO2003000695A1 (fr) * 2001-06-23 2003-01-03 Aventis Pharmaceuticals Inc Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases
WO2003031606A2 (fr) * 2001-10-10 2003-04-17 Astrazeneca Ab Structure cristalline d'une enzyme et ses applications
WO2004065378A1 (fr) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire
CN1688573A (zh) * 2002-08-23 2005-10-26 希龙公司 糖原合成酶激酶3的吡咯基抑制剂
WO2005110410A2 (fr) * 2004-05-14 2005-11-24 Abbott Laboratories Inhibiteurs de kinases en tant qu'agents therapeutiques
WO2006002051A1 (fr) * 2004-06-15 2006-01-05 Schering Corporation Composes tricycliques et leur utilisation comme antagonistes du mglur1
WO2006074984A1 (fr) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines constituant des inhibiteurs de kinases specifiques du cycle cellulaire
WO2006074985A1 (fr) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrimidines heterocycliques anneles a 5 elements utilises comme inhibiteurs de kinase
WO2006107771A2 (fr) * 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogues de ceux-ci, et procedes
WO2006122137A1 (fr) * 2005-05-10 2006-11-16 Bristol-Myers Squibb Company Composes tricycliques bases sur 1,6 -dihydro-1,3,5,6-tetraaza-as-indacene et compositions pharmaceutiques les comprenant, utilises en tant qu'inhibiteurs de l'activite d'enzyme ikk
WO2007007919A2 (fr) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Nouveaux composes
WO2007022268A2 (fr) * 2005-08-16 2007-02-22 Irm Llc Composés et compositions en tant qu'inhibiteurs de protéine kinase
JP2007510730A (ja) * 2003-11-10 2007-04-26 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニルテトラヒドロ−３ｈ−ベンゾインドール−８−アミン化合物
WO2007079164A2 (fr) * 2005-12-29 2007-07-12 Abbott Laboratories Inhibiteurs de protéines kinases
WO2007077949A1 (fr) * 2005-12-28 2007-07-12 Astellas Pharma Inc. Inhibiteurs heterocycliques de la janus kinase 3
WO2008063287A2 (fr) * 2006-10-06 2008-05-29 Abbott Laboratories Nouveaux imidazothiazoles et imidazoxazoles
CA2675288A1 (fr) * 2007-01-12 2008-07-17 Astellas Pharma Inc. Compose de pyridine condensee
WO2008094602A2 (fr) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Modulateurs de kinases mitotiques
WO2008112695A2 (fr) * 2007-03-12 2008-09-18 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
WO2008121748A2 (fr) * 2007-03-30 2008-10-09 King Pharmaceuticals Research And Development,Inc. Antagonistes du récepteur a2a de l'adénosine
CN101321760A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
WO2009005675A1 (fr) * 2007-06-28 2009-01-08 Abbott Laboratories Nouvelles triazolopyridazines
JP2009526869A (ja) * 2006-02-15 2009-07-23 アボット・ラボラトリーズ ピラゾロキノロン類は強力なｐａｒｐ阻害薬である
WO2009098236A1 (fr) * 2008-02-06 2009-08-13 Novartis Ag Composés hétérocycliques
WO2009152133A1 (fr) * 2008-06-10 2009-12-17 Abbott Laboratories Nouveaux composés tricycliques
WO2010119875A1 (fr) * 2009-04-14 2010-10-21 アステラス製薬株式会社 Dérivé de pyrrolopyridine condensé
CN102711476B (zh) * 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB716327A (en) 1951-09-05 1954-10-06 Ici Ltd New heterocyclic compounds
US3663559A (en) 1969-12-03 1972-05-16 Union Carbide Corp Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JP2988711B2 (ja) 1989-10-20 1999-12-13 協和醗酵工業株式会社 縮合プリン誘導体
HUT63170A (en) 1990-01-11 1993-07-28 Isis Pharmaceuticals Inc Process and composition for detecting and modifying rna activity and gene expression
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
WO1992009304A1 (fr) 1990-11-26 1992-06-11 Recker Robert R Traitement de l'osteoporose utilisant un facteur de liberation d'hormone de croissance (grf) combine a une hormone parathyroidienne (pth)
CA2736076A1 (fr) 1991-03-18 1992-09-19 New York University Anticorps monoclonaux et chimeriques specifiques du facteur de necrose tumorale humain
KR100207360B1 (ko) 1991-06-14 1999-07-15 돈 더블유. 슈미츠 이미다조[1,5,-a]퀸옥살린
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
NZ262797A (en) 1993-02-26 1997-08-22 Schering Corp Polycyclic guanine derivatives, purine and pyrimidine precursors; medicaments
US5733905A (en) 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5736540A (en) 1993-07-29 1998-04-07 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (ru) 1994-12-23 2000-10-27 Варнер-Ламберт Компани Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5763137A (en) 1995-08-04 1998-06-09 Agfa-Gevaert, N.V. Method for making a lithographic printing plate
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CA2420967A1 (fr) 2000-08-07 2002-02-14 Neurogen Corporation Composes heterocycliques en tant que ligands du recepteur gabaa
US20050176796A1 (en) 2002-02-19 2005-08-11 D'alessio Roberto Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006010567A1 (fr) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines et pyrido[3',2':4,5]furo[3,2-d]pyrimidines substituees utilisees comme inhibiteurs de la pde 4 et de la liberation du tnf$g(a)
ZA200704888B (en) 2004-11-22 2009-02-25 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US20060183758A1 (en) 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
CN101223168A (zh) * 2005-07-14 2008-07-16 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
WO2007014011A2 (fr) 2005-07-21 2007-02-01 Ardea Biosciences, Inc. Inhibiteurs n-(arylamino)-sulfonamide de mek
WO2007035935A1 (fr) 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. Procede de preparation de 1h-imidazo[4,5-c]pyridines et d'analogues de ceux-ci
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CN101641447A (zh) 2007-04-04 2010-02-03 霍夫曼-拉罗奇有限公司 乙酰氧基酮的微生物还原
CA2924418A1 (fr) 2007-07-30 2009-02-05 Jean-Michel Vernier Derives de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procedes d'utilisation et procedes de preparation de ceux-ci
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
CA2716223A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de kinase pyrrolopyrazine
KR101261514B1 (ko) 2008-02-25 2013-05-07 에프. 호프만-라 로슈 아게 피롤로피라진 키나아제 저해제
WO2009108827A1 (fr) 2008-02-29 2009-09-03 Wyeth Pyrazolo[1,5-a]pyrimidines tricycliques condensées, procédés pour les préparer et leurs utilisations
CA2728559A1 (fr) * 2008-07-03 2010-01-07 Exelixis Inc. Modulateurs de cdk
US8361962B2 (en) * 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
AU2010326030A1 (en) * 2009-12-01 2012-06-07 Abbvie Inc. Novel tricyclic compounds
WO2011156698A2 (fr) 2010-06-11 2011-12-15 Abbott Laboratories Nouveaux composés de pyrazolo[3,4-d]pyrimidine
WO2012149280A2 (fr) 2011-04-29 2012-11-01 Abbott Laboratories Nouveaux composés tricycliques
US20130072470A1 (en) 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
WO2015061665A1 (fr) 2013-10-24 2015-04-30 Abbvie Inc. Inhibiteur sélectif de jak1 et ses utilisations
SG10201913999PA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053474A (en) * 1976-04-21 1977-10-11 E. R. Squibb & Sons, Inc. Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
WO1995019970A1 (fr) * 1994-01-25 1995-07-27 Warner-Lambert Company Composes tricycliques pouvant inhiber les tyrosines kinases de la famille des recepteurs du facteur de croissance epidermique
WO1999045009A1 (fr) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Inhibiteurs de la proteine tyrosine kinase, a base d'imidazopyrazine a substitution heterocyclo
JP2001233876A (ja) * 1999-12-13 2001-08-28 Eisai Co Ltd 三環式縮合異項環化合物、その製造法およびその医薬
WO2003000695A1 (fr) * 2001-06-23 2003-01-03 Aventis Pharmaceuticals Inc Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases
WO2003031606A2 (fr) * 2001-10-10 2003-04-17 Astrazeneca Ab Structure cristalline d'une enzyme et ses applications
CN1688573A (zh) * 2002-08-23 2005-10-26 希龙公司 糖原合成酶激酶3的吡咯基抑制剂
WO2004065378A1 (fr) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire
JP2007510730A (ja) * 2003-11-10 2007-04-26 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニルテトラヒドロ−３ｈ−ベンゾインドール−８−アミン化合物
WO2005110410A2 (fr) * 2004-05-14 2005-11-24 Abbott Laboratories Inhibiteurs de kinases en tant qu'agents therapeutiques
WO2006002051A1 (fr) * 2004-06-15 2006-01-05 Schering Corporation Composes tricycliques et leur utilisation comme antagonistes du mglur1
WO2006074985A1 (fr) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrimidines heterocycliques anneles a 5 elements utilises comme inhibiteurs de kinase
WO2006074984A1 (fr) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines constituant des inhibiteurs de kinases specifiques du cycle cellulaire
WO2006107771A2 (fr) * 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogues de ceux-ci, et procedes
WO2006122137A1 (fr) * 2005-05-10 2006-11-16 Bristol-Myers Squibb Company Composes tricycliques bases sur 1,6 -dihydro-1,3,5,6-tetraaza-as-indacene et compositions pharmaceutiques les comprenant, utilises en tant qu'inhibiteurs de l'activite d'enzyme ikk
WO2007007919A2 (fr) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Nouveaux composes
CN101291938A (zh) * 2005-08-16 2008-10-22 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2007022268A2 (fr) * 2005-08-16 2007-02-22 Irm Llc Composés et compositions en tant qu'inhibiteurs de protéine kinase
CN101321760A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
WO2007077949A1 (fr) * 2005-12-28 2007-07-12 Astellas Pharma Inc. Inhibiteurs heterocycliques de la janus kinase 3
WO2007079164A2 (fr) * 2005-12-29 2007-07-12 Abbott Laboratories Inhibiteurs de protéines kinases
JP2009526869A (ja) * 2006-02-15 2009-07-23 アボット・ラボラトリーズ ピラゾロキノロン類は強力なｐａｒｐ阻害薬である
WO2008063287A2 (fr) * 2006-10-06 2008-05-29 Abbott Laboratories Nouveaux imidazothiazoles et imidazoxazoles
WO2008084861A1 (fr) * 2007-01-12 2008-07-17 Astellas Pharma Inc. Composé de pyridine condensée
CA2675288A1 (fr) * 2007-01-12 2008-07-17 Astellas Pharma Inc. Compose de pyridine condensee
EP2123651A1 (fr) * 2007-01-12 2009-11-25 Astellas Pharma Inc. Composé de pyridine condensée
WO2008094602A2 (fr) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Modulateurs de kinases mitotiques
WO2008112695A2 (fr) * 2007-03-12 2008-09-18 Irm Llc Inhibiteurs de protéine kinase et procédés d'utilisation de ceux-ci
WO2008121748A2 (fr) * 2007-03-30 2008-10-09 King Pharmaceuticals Research And Development,Inc. Antagonistes du récepteur a2a de l'adénosine
WO2009005675A1 (fr) * 2007-06-28 2009-01-08 Abbott Laboratories Nouvelles triazolopyridazines
WO2009098236A1 (fr) * 2008-02-06 2009-08-13 Novartis Ag Composés hétérocycliques
WO2009152133A1 (fr) * 2008-06-10 2009-12-17 Abbott Laboratories Nouveaux composés tricycliques
CN102118968A (zh) * 2008-06-10 2011-07-06 雅培制药有限公司 新的三环化合物
WO2010119875A1 (fr) * 2009-04-14 2010-10-21 アステラス製薬株式会社 Dérivé de pyrrolopyridine condensé
CN102711476B (zh) * 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANTHONY J MILICI，ET AL.: "Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis", 《ARTHRITIS RESEARCH & THERAPY》 *
CHRISTOPHE ROCHAIS，ET AL.: "Synthesis of new dipyrrolo- and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1e5, GSK-3) inhibitors", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
G.G. DUBININA，ET AL.: "Novel 5,7-disubstituted 6-amino-5H-pyrrolo [3,2-b]pyrazine-2,3-dicarbonitriles,the promising protein kinase inhibitors with antiproliferative activity", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
HISHAM A. ABD EL-NABI: "1-Aryl-2-chloro-5-methoxy-1H-3-pyrrolecarbaldehyde as synthons for fused heterocycles: synthesis of pyrazolo[3,4-d]pyrrolo[2,3-b]pyridine derivatives", 《JOURNAL OF CHEMICAL RESEARCH》 *
JENNIFER G WALKER: "The Jak-STAT pathway in rheumatoid arthritis.", 《THE JOURNAL OF RHEUMATOLOGY VOLUME 32》 *
M. RAVI SHASHI NAYANA，ET AL.: "CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
SANJAY，ET AL.: "A novel synthesis of di(1-methylazacycloalkeno)[2,3-b:2′,3′-d]pyridines through annulation on lactam acetals", 《TETRAHEDRON LETTERS》 *
何新华 等: "酪氨酸激酶Jak3 抑制剂的研究进展", 《中国药物化学杂志》 *

Also Published As

Publication number Publication date
DOP2012000151A (es) 2012-09-30
CN109053742B (zh) 2021-06-15
CY2020007I1 (el) 2020-05-29
EP3266786A1 (fr) 2018-01-10
US20160222020A1 (en) 2016-08-04
PL2506716T3 (pl) 2017-10-31
DK2506716T3 (en) 2017-09-04
AU2018201663B2 (en) 2020-03-05
CN102711476A (zh) 2012-10-03
JP5607174B2 (ja) 2014-10-15
AU2010326108A1 (en) 2012-06-14
NZ600161A (en) 2014-08-29
TWI600656B (zh) 2017-10-01
SG10201407976UA (en) 2015-01-29
ZA201203999B (en) 2016-01-27
AU2018201663A1 (en) 2018-03-29
ES2637588T3 (es) 2017-10-13
CL2012001397A1 (es) 2012-09-14
RU2015144809A3 (fr) 2019-01-11
RU2570416C2 (ru) 2015-12-10
NL301035I2 (nl) 2020-04-15
UY33071A (es) 2011-05-31
RU2012127306A (ru) 2014-01-10
PH12012501076B1 (en) 2018-07-04
PE20121336A1 (es) 2012-11-03
JP5985557B2 (ja) 2016-09-06
JP2015007094A (ja) 2015-01-15
AU2010326108B2 (en) 2015-12-24
AU2010326108C1 (en) 2018-06-21
AU2016201825B2 (en) 2017-12-07
TW201802091A (zh) 2018-01-16
BR112012013349B1 (pt) 2019-10-22
KR20140015151A (ko) 2014-02-06
AU2016201825A1 (en) 2016-04-14
IL253516A0 (en) 2017-09-28
JP2017002068A (ja) 2017-01-05
JP2013512280A (ja) 2013-04-11
PT2506716T (pt) 2017-08-24
IL261778A (en) 2018-10-31
CR20170159A (es) 2017-06-26
ECSP12011979A (es) 2012-07-31
HUS2000008I1 (hu) 2020-03-30
HUE033099T2 (en) 2017-11-28
DOP2016000017A (es) 2016-03-31
CA2991896A1 (fr) 2011-06-09
LUC00149I1 (fr) 2020-03-09
CA2781891A1 (fr) 2011-06-09
US20110311474A1 (en) 2011-12-22
HRP20171175T1 (hr) 2017-10-06
CN104370909A (zh) 2015-02-25
KR20180101626A (ko) 2018-09-12
MX346959B (es) 2017-04-06
AR079234A1 (es) 2012-01-04
CO6561771A2 (es) 2012-11-15
LTPA2020505I1 (lt) 2020-04-10
MY167076A (en) 2018-08-10
NO2020006I1 (no) 2020-03-11
IL248466A (en) 2017-07-31
CN104370909B (zh) 2018-09-11
RU2711869C2 (ru) 2020-01-22
CA2781891C (fr) 2018-02-13
CR20120348A (es) 2012-10-04
LT2506716T (lt) 2017-08-25
LTC2506716I2 (lt) 2022-06-27
EP2506716A1 (fr) 2012-10-10
PH12012501076A1 (en) 2017-07-21
WO2011068881A1 (fr) 2011-06-09
NL301035I1 (nl) 2020-03-25
BR112012013349A2 (pt) 2015-09-15
CN102711476B (zh) 2014-12-03
US20130216497A1 (en) 2013-08-22
HK1256947A1 (zh) 2019-10-04
EP2506716A4 (fr) 2013-05-29
SI2506716T1 (sl) 2017-10-30
TWI500620B (zh) 2015-09-21
KR101785257B1 (ko) 2017-10-16
RU2570416C9 (ru) 2020-03-18
TW201125869A (en) 2011-08-01
US20210061813A1 (en) 2021-03-04
JP6298114B2 (ja) 2018-03-20
HUS000500I2 (hu) 2021-03-29
RU2015144809A (ru) 2019-01-11
CY1119175T1 (el) 2018-02-14
RS56317B1 (sr) 2017-12-29
IL253516B (en) 2018-10-31
TW201546074A (zh) 2015-12-16
USRE47221E1 (en) 2019-02-05
EP2506716B1 (fr) 2017-05-17
IL220054A0 (en) 2012-07-31
CY2020007I2 (el) 2020-11-25
RU2711869C3 (ru) 2022-02-02
SG181472A1 (en) 2012-07-30
CN109053742A (zh) 2018-12-21
EP3950692A1 (fr) 2022-02-09
ME02800B (fr) 2018-01-20
KR20170118230A (ko) 2017-10-24
US8426411B2 (en) 2013-04-23
MX2012006311A (es) 2012-09-12
PH12016501009A1 (en) 2017-10-18
AU2020201390A1 (en) 2020-03-12
IL220054A (en) 2016-10-31
LUC00149I2 (fr) 2021-02-15

Similar Documents

Publication Publication Date Title
CN104370909B (zh) 三环化合物
CN102118968A (zh) 新的三环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1256947

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181109

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1256947

Country of ref document: HK